Open AccessUse of Curcumin with Tyrosine Kinase Inhibitors in EGFR-mutant Non-Small Cell Lung Cancer. A Phase I prospective Cohort Trial
Author(s) -
G. Kasymjanova
Publication year - 2021
Publication title -
hsoa journal of alternative, complementary and integrative medicine
Language(s) - English
Resource type - Journals
ISSN - 2470-7562
DOI - 10.24966/acim-7562/100201
Subject(s) - curcumin , lung cancer , medicine , oncology , randomized controlled trial , clinical trial , prospective cohort study , cancer , tyrosine kinase , pharmacology , receptor
Our study is the first prospective clinical study using combination of curcumin and EGFR-TKIs in metastatic lung cancer patients. The future randomized larger-scale clinical trials using this combination is feasible and safe. RCT will seek to assess the potential effects on survival and response to TKIs.